Sugi Predict

Sugi Predict / Compounds / SCHEMBL7634010

SCHEMBL7634010

SCHEMBL7634010

CCOc1cc(C#N)ccc1F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV4 Q9HBA0 2/20 0.56
▸ HTT P42858 2/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ DRD4 P21917 1/20 0.40
▸ SLC6A9 P48067 1/20 0.40
▸ GRM5 P41594 1/20 0.40
▸ S1PR1 P21453 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ PDE4A P27815 1/20 0.39
▸ PDE4B Q07343 1/20 0.39
▸ PDE4C Q08493 1/20 0.39
▸ PDE4D Q08499 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ PTGDR2 Q9Y5Y4 1/20 0.39
▸ GABRG2 P18507 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4727931 0.86 TRPV4 (0.53) TRPV4L3MBTL1SLC6A9S1PR1ALDH1A1
SCHEMBL14871861 0.85 ALDH1A1 (0.43) TRPV4HTTL3MBTL1SLC6A9ALDH1A1
SCHEMBL1402437 0.83 TRPV4 (0.61) TRPV4DRD4GRM5S1PR1ALDH1A1
SCHEMBL2527854 0.83 TRPV4 (0.40) TRPV4PTGDR2MGLL
SCHEMBL1476726 0.83 TRPV4 (0.42) TRPV4HTTGRM5
SCHEMBL16956913 0.82 HTT (0.45) TRPV4HTTL3MBTL1POLBALDH1A1
SCHEMBL5418640 0.81 TRPV4 (0.59) TRPV4DRD4GRM5S1PR1ALDH1A1
SCHEMBL19851607 0.81 TRPV4 (0.45) TRPV4SLC6A9ALDH1A1MGLL
SCHEMBL28710980 0.81 AR (0.40) TRPV4L3MBTL1ALDH1A1MAPTPTGDR2
SCHEMBL350999 0.79 AR (0.51) TRPV4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220169645-A1 COMPOUNDS AS BRUTON TYROSINE KINASE INHIBITORS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF Eternity Bioscience Inc. 2022-06-02 — — US disclosed
US-20220169645-A1 COMPOUNDS AS BRUTON TYROSINE KINASE INHIBITORS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF Eternity Bioscience Inc. 2022-06-02 — — US disclosed
US-8658639-B2 N-substituted-cyclic amino derivative DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2014-02-25 — — US disclosed
US-8389511-B2 Bicyclic heterocyclic derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-03-05 — — US disclosed
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-05-17 — — US disclosed
US-20110190278-A1 BICYCLIC HETEROCYCLIC DERIVATIVE DAINIPPON SUMITOMO PHARMA CO. 2011-08-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190278-A1 BICYCLIC HETEROCYCLIC DERIVATIVE REN, AGTR1, AGTR2 TRPV4 2569/4885HTT 3469/4885L3MBTL1 3310/4885
US-20220169645-A1 COMPOUNDS AS BRUTON TYROSINE KINASE INHIBITORS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF BTK, LYN, LCK TRPV4 4571/4885HTT 4199/4885L3MBTL1 3199/4885
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE REN, AGTR1, AGTR2 TRPV4 2185/4885HTT 4266/4885L3MBTL1 2743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.